Regeneron Pharmaceuticals REGN Reimbursement Of Commercialization Related Expenses — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's reimbursement of commercialization related expenses — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's reimbursement of commercialization related expenses — revenue?
- Regeneron Pharmaceuticals (REGN) reported reimbursement of commercialization related expenses — revenue of $184.1M in Q1 2026.
- How has Regeneron Pharmaceuticals's reimbursement of commercialization related expenses — revenue changed year-over-year?
- Regeneron Pharmaceuticals's reimbursement of commercialization related expenses — revenue increased by 15.6% year-over-year, from $159.2M to $184.1M.
- What is the long-term trend for Regeneron Pharmaceuticals's reimbursement of commercialization related expenses — revenue?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's reimbursement of commercialization related expenses — revenue has grown at a 22.7% compound annual growth rate (CAGR), from $321.3M to $729.3M.
- What does reimbursement of commercialization related expenses — revenue mean?
- Revenue earned by recovering commercialization costs from collaboration partners.
- How do you interpret reimbursement of commercialization related expenses — revenue?
- An increase suggests higher shared commercial activity or a shift in the cost-sharing structure of a partnership, while a decrease may indicate reduced collaborative marketing efforts or changes in contractual reimbursement terms.
- How does reimbursement of commercialization related expenses — revenue compare across companies?
- Similar to 'collaboration revenue' or 'cost-sharing revenue' found in other biopharmaceutical companies with significant R&D and commercial partnerships, such as those with co-promotion agreements.